Overview

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-6231 in Healthy Adults

Status:
Recruiting

Trial end date:
2022-11-15

Target enrollment:

Participant gender:

Summary

The main goal of this study is to evaluate the safety and tolerability of escalating doses of a single subcutaneous (SC) administration of mRNA-6231.

Phase:

Phase 1

Details

Lead Sponsor:

ModernaTX, Inc.